Divarasib significantly improved PFS (9.8 vs 5.7 m) and OS (12 vs 17.7) vs control (soto or ada) with a manageable safety profile (GI toxicity) in previously treated advanced/metastatic KRAS G12C-mutated NSCLC. @myESMO @OncoAlert proud to be part of it. @CHUdeToulouse #ESMO26